ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

GNTA Genenta Science SPA

3.083
-0.017 (-0.55%)
01 Jul 2024 - Closed
Delayed by 15 minutes
Name Symbol Market Type
Genenta Science SPA NASDAQ:GNTA NASDAQ Depository Receipt
  Price Change % Change Price Bid Price Offer Price High Price Low Price Open Price Traded Last Trade
  -0.017 -0.55% 3.083 1.24 4.83 3.12 3.06 3.10 4,641 21:23:53

Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)

25/10/2022 10:14pm

Edgar (US Regulatory)


 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 UNDER

THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2022

 

Commission File Number: 001-41115

 

GENENTA SCIENCE S.P.A.

(Translation of registrant’s name into English)

 

Via Olgettina No. 58

20132 Milan, Italy

(Address of Principal Executive Offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒   Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

Other Events

 

On October 24, 2022, Genenta Science S.p.A. (the “Company”) issued a press release (the “Press Release”) announcing the Company’s business update and financial results for the six months ended June 30, 2022. A copy of the Press Release is furnished as Exhibit 99.1 hereto.

 

Exhibits

 

Exhibit No.   Description
99.1   Press Release, dated October 24, 2022, regarding the Registrant’s business update and financial results for the six months ended June 30, 2022.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GENENTA SCIENCE S.P.A.
   
  By: /s/ Richard B. Slansky
  Name: Richard B. Slansky
  Title: Chief Financial Officer

 

Dated: October 25, 2022

 

 

 

1 Year Genenta Science Chart

1 Year Genenta Science Chart

1 Month Genenta Science Chart

1 Month Genenta Science Chart

Your Recent History

Delayed Upgrade Clock